title: Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study.
abstract: BACKGROUND Currently available antithrombotic prophylaxis is not perfectly reliable in elderly patients. The aim of this retrospective study was to evaluate the efficacy and safety of Compound Danshen Tablet (CDT) in preventing thromboembolism in multiple myeloma (MM) patients treated with thalidomide-based regimens. MATERIAL AND METHODS MM patients treated with thalidomide-based regimens were retrospectively reviewed between January 2008 and March 2015. Patients were categorized into 3 cohorts based on thromboembolic prophylaxis used: CDT, Warfarin Tablet, and no prophylaxis. Venous thromboembolism (VTE), other adverse effects (AEs), and the changes of D-dimer and fibrinogen levels were monitored. RESULTS Seven out of 313 MM patients (2.24%) developed venous thrombosis events (VTE) in this retrospective study, all clustering in the no prophylaxis cohort. Three patients of the Warfarin cohort (3.19%) experienced hemorrhage. Neither VTE events nor serious AEs were observed in the CDT cohort. Following Compound Danshen or Warfarin treatment for 3 months, the D-dimer and fibrinogen levels (in particular the D-dimer level) (all P<0.05), were obviously decreased relative to their respective baselines and the no prophylaxis cohort. In contrast, the 2 blotting parameters were significantly increased in the no prophylaxis cohort relative to the baseline level (All P<0.05), and were even higher in the patients experiencing VTE compared to the no VTE patients (P<0.0001 and P=0.016, respectively). CONCLUSIONS Our findings indicate CDT is an effective therapy for preventing VTE in MM patients treated with thalidomide-based regimens, and is well tolerated in long-term use.
authors.affiliation: Department of Leukemia, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China (mainland).
authors.forename: Qing-Song
authors.initials: QS
authors.lastname: Yin
authors.affiliation: Department of Leukemia, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China (mainland).
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Leukemia, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China (mainland).
authors.forename: Rui-Hua
authors.initials: RH
authors.lastname: Mi
authors.affiliation: Department of Leukemia, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China (mainland).
authors.forename: Hao
authors.initials: H
authors.lastname: Ai
authors.affiliation: Department of Leukemia, The Central Hospital of Xinxiang, Xinxiang, Henan, China (mainland).
authors.forename: Jun-Jie
authors.initials: JJ
authors.lastname: Yin
authors.affiliation: Department of Leukemia , The Second People's Hospital of Jiaozuo, Jiaozuo, Henan, China (mainland).
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Liu
authors.affiliation: Department of Leukemia , Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China (mainland).
authors.forename: Xu-Dong
authors.initials: XD
authors.lastname: Wei
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy*; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors; D027561:Salvia miltiorrhiza; D013607:Tablets; D013792:Thalidomide / Q000009:adverse effects; D054556:Venous Thromboembolism / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage
chemical_list: D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; D028321:Plant Preparations; D013607:Tablets; C036309:fibrin fragment D; D013792:Thalidomide; D014859:Warfarin